276 related articles for article (PubMed ID: 18565735)
21. Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea.
Falanga V; Medsger TA; Reichlin M
Arch Dermatol; 1987 Mar; 123(3):350-3. PubMed ID: 3545090
[TBL] [Abstract][Full Text] [Related]
22. Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis.
Mimura Y; Ihn H; Jinnin M; Asano Y; Yamane K; Yazawa N; Tamaki K
Br J Dermatol; 2004 Oct; 151(4):803-8. PubMed ID: 15491420
[TBL] [Abstract][Full Text] [Related]
23. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
Hénault J; Tremblay M; Clément I; Raymond Y; Senécal JL
Arthritis Rheum; 2004 Oct; 50(10):3265-74. PubMed ID: 15476238
[TBL] [Abstract][Full Text] [Related]
24. Serum concentration of procollagen type I carboxyterminal propeptide in localized scleroderma.
Kikuchi K; Sato S; Kadono T; Ihn H; Takehara K
Arch Dermatol; 1994 Oct; 130(10):1269-72. PubMed ID: 7944508
[TBL] [Abstract][Full Text] [Related]
25. [Scleroderma].
Scharffetter K; Kind P; Wollny-Protzel D; Schuppe HC; Lakomek HJ; Goerz G
Z Hautkr; 1990 Mar; 65(3):237-42, 245-6. PubMed ID: 2187309
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma.
Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K
Br J Dermatol; 1996 May; 134(5):843-7. PubMed ID: 8736323
[TBL] [Abstract][Full Text] [Related]
27. Antinuclear antibodies in children with localized scleroderma.
Rosenberg AM; Uziel Y; Krafchik BR; Hauta SA; Prokopchuk PA; Silverman ED; Laxer RM
J Rheumatol; 1995 Dec; 22(12):2337-43. PubMed ID: 8835572
[TBL] [Abstract][Full Text] [Related]
28. Serum matrix metalloproteinase-3 in systemic sclerosis.
Jinnin M; Ihn H; Asano Y; Yamane K; Yazawa N; Tamaki K
Arch Dermatol Res; 2004 Jun; 296(1):25-9. PubMed ID: 15095096
[TBL] [Abstract][Full Text] [Related]
29. Rheumatoid factor isotypes in localized scleroderma.
Mimura Y; Ihn H; Jinnin M; Asano Y; Yamane K; Tamaki K
Clin Exp Dermatol; 2005 Jul; 30(4):405-8. PubMed ID: 15953082
[TBL] [Abstract][Full Text] [Related]
30. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.
Reitamo S; Remitz A; Varga J; Ceska M; Effenberger F; Jimenez S; Uitto J
Arch Dermatol; 1993 Feb; 129(2):189-93. PubMed ID: 8434976
[TBL] [Abstract][Full Text] [Related]
31. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease.
Ihn H; Yazawa N; Kubo M; Yamane K; Sato S; Fujimoto M; Kikuchi K; Soma Y; Tamaki K
J Rheumatol; 2000 Mar; 27(3):698-702. PubMed ID: 10743811
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of serum matrix metalloproteinase-13 levels in patients with localized scleroderma.
Asano Y; Ihn H; Kubo M; Jinnin M; Mimura Y; Ashida R; Tamaki K
Clin Exp Rheumatol; 2006; 24(4):394-9. PubMed ID: 16956429
[TBL] [Abstract][Full Text] [Related]
33. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
Jimenez-Boj E; Kedersha N; Tohidast-Akrad M; Karlhofer FM; Stummvoll G; Zimmermann C; Ulrich W; Guiducci S; Hoefler E; Aringer M; Schett G; Matucci-Cerinic M; Smolen JS; Steiner G
Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
[TBL] [Abstract][Full Text] [Related]
34. Autoantibody against a protease domain of caspase-8 in patients with systemic sclerosis.
Yamaoka T; Ogawa F; Muroi E; Hara T; Komura K; Iwata Y; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
Clin Exp Rheumatol; 2008; 26(6):998-1004. PubMed ID: 19210862
[TBL] [Abstract][Full Text] [Related]
35. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid.
Iwata Y; Komura K; Kodera M; Usuda T; Yokoyama Y; Hara T; Muroi E; Ogawa F; Takenaka M; Sato S
Arch Dermatol; 2008 Jan; 144(1):41-8. PubMed ID: 18209167
[TBL] [Abstract][Full Text] [Related]
36. Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma. A single-center study.
Arkachaisri T; Fertig N; Pino S; Medsger TA
J Rheumatol; 2008 Dec; 35(12):2439-44. PubMed ID: 19004036
[TBL] [Abstract][Full Text] [Related]
37. [Identification of human platelet specific functional antibody and its fragments].
Chu XX; Hou M; Zhu YY; Peng J; Ji XB; Zhang F; Wang L
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3464-8. PubMed ID: 16686061
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis.
Asano Y; Ihn H; Kubo M; Jinnin M; Mimura Y; Ashida R; Tamaki K
Rheumatology (Oxford); 2006 Mar; 45(3):303-7. PubMed ID: 16278285
[TBL] [Abstract][Full Text] [Related]
39. Anti-annexin V antibodies and digital ischemia in patients with scleroderma.
Sugiura K; Muro Y
J Rheumatol; 1999 Oct; 26(10):2168-72. PubMed ID: 10529134
[TBL] [Abstract][Full Text] [Related]
40. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis.
Hu PQ; Fertig N; Medsger TA; Wright TM
Arthritis Rheum; 2003 May; 48(5):1363-73. PubMed ID: 12746909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
